Literature DB >> 20234172

Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Jay F Dorsey1, Melissa L Dowling, Mijin Kim, Ranh Voong, Lawrence J Solin, Gary D Kao.   

Abstract

Mitotic spindle-disrupting agents target and disrupt microtubule dynamics. These agents include clinically important chemotherapies, including taxanes (paclitaxel (Taxol), docetaxel (Taxotere)) and vinca alkaloids (vincristine (Oncovin), vinblastine). Taxanes are a standard component of treatment for many malignancies, often in conjunction with other cytotoxic agents. However, the optimal sequencing of these treatments and whether efficacy may be influenced by in vitro cellular growth conditions remain incompletely investigated. Yet such preclinical investigations may guide clinical decision making. We therefore studied the effect of cell density on rapid killing by paclitaxel and vincristine. Breast, ovarian and prostate cancer cells were sensitive to rapid killing by either agent when grown at low density, but were markedly resistant when grown at high density, i.e. nearly confluent. The resistance of densely growing cells to rapid killing by these drugs translated to increased clonogenic survival. Pretreatment of densely growing cancer cells with cisplatin followed by paclitaxel, partially reversed the treatment resistance. Gene ontology associations from microarray analyses of cells grown at low and high density, suggested roles for membrane signal transduction and adhesion, but potentially also DNA damage repair and metabolism. Taken together, the treatment resistance at higher cell density may be associated with a lower proportion of active cycling in cells growing at high density as well as transduction of survival signals induced by increased cell-cell adhesion. Collectively these findings suggest mechanisms by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234172      PMCID: PMC3621729          DOI: 10.4161/cbt.9.10.11453

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  45 in total

1.  Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels.

Authors:  G Tudor; A Aguilera; D O Halverson; N D Laing; E A Sausville
Journal:  Cell Death Differ       Date:  2000-06       Impact factor: 15.828

2.  Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells.

Authors:  G D Kao; W G McKenna; T J Yen
Journal:  Oncogene       Date:  2001-06-14       Impact factor: 9.867

Review 3.  The role of beta-tubulin isotypes in resistance to antimitotic drugs.

Authors:  C A Burkhart; M Kavallaris; S Band Horwitz
Journal:  Biochim Biophys Acta       Date:  2001

Review 4.  The spindle checkpoint: structural insights into dynamic signalling.

Authors:  Andrea Musacchio; Kevin G Hardwick
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

Review 5.  Recognition of cisplatin adducts by cellular proteins.

Authors:  M Kartalou; J M Essigmann
Journal:  Mutat Res       Date:  2001-07-01       Impact factor: 2.433

6.  Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.

Authors:  V K Ngan; K Bellman; B T Hill; L Wilson; M A Jordan
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

7.  Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.

Authors:  Z Duan; A J Feller; R T Penson; B A Chabner; M V Seiden
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

Review 8.  Primary chemotherapy with docetaxel for the management of breast cancer.

Authors:  Vicente Valero
Journal:  Oncology (Williston Park)       Date:  2002-06       Impact factor: 2.990

9.  Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.

Authors:  Sarah Everitt; Rodney J Hicks; David Ball; Tomas Kron; Michal Schneider-Kolsky; Tania Walter; David Binns; Michael Mac Manus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-20       Impact factor: 7.038

10.  MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.

Authors:  G K Chen; G E Durán; A Mangili; L Beketic-Oreskovic; B I Sikic
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

View more
  7 in total

1.  Tubulin-targeting agent combination therapies: dosing schedule could matter.

Authors:  Eric Solary
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

2.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

3.  Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma.

Authors:  Diane M Kambach; Alan S Halim; A Gesine Cauer; Qian Sun; Carlos A Tristan; Orieta Celiku; Aparna H Kesarwala; Uma Shankavaram; Eric Batchelor; Jayne M Stommel
Journal:  Oncotarget       Date:  2017-02-28

4.  Guanylate-binding proteins induce apoptosis of leukemia cells by regulating MCL-1 and BAK.

Authors:  Yongyang Luo; Hanyong Jin; Je Hyeong Kim; Jeehyeon Bae
Journal:  Oncogenesis       Date:  2021-07-22       Impact factor: 7.485

5.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Med Chem (Los Angeles)       Date:  2013-05

6.  Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Alessandro Colapietro; Francesco Marampon; Roberta Sferra; Simona Pompili; Leda Assunta Biordi; Roberto Iorio; Vincenzo Flati; Christian Argueta; Yosef Landesman; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  Oncotarget       Date:  2017-11-30

7.  LXRβ controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1.

Authors:  Deven Patel; Fahim Ahmad; Diane M Kambach; Qian Sun; Alan S Halim; Tamalee Kramp; Kevin A Camphausen; Jayne M Stommel
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.